Neurozen
Neurozen is a leading Korean company specializing in AI-powered neuroimaging and genetic solutions for the early detection and prediction of Alzheimer's disease. They leverage the largest Asian dementia cohort, licensed exclusively from the National Research Center for Dementia (NRCD), which includes multimodal data such as clinical, neuropsychological, imaging (MRI and PET), and genomic data. Neurozen utilizes deep learning technologies to develop normative databases for accurate comparisons and informed diagnoses. Their product offerings include AlzgenAI for genomics-based prediction, MemoAI for cognition-based prediction, and NeuroAI for MRI and APOE genotype-based prediction. The company aims to provide clinical tools that predict, quantify, and monitor neurodegeneration, enabling physicians to make better clinical decisions and improve patients' quality of life. They are backed by a diverse network of experts and have a mission to be the global number one in dementia prediction technology.
Neurozen
Neurozen is a leading Korean company specializing in AI-powered neuroimaging and genetic solutions for the early detection and prediction of Alzheimer's disease. They leverage the largest Asian dementia cohort, licensed exclusively from the National Research Center for Dementia (NRCD), which includes multimodal data such as clinical, neuropsychological, imaging (MRI and PET), and genomic data. Neurozen utilizes deep learning technologies to develop normative databases for accurate comparisons and informed diagnoses. Their product offerings include AlzgenAI for genomics-based prediction, MemoAI for cognition-based prediction, and NeuroAI for MRI and APOE genotype-based prediction. The company aims to provide clinical tools that predict, quantify, and monitor neurodegeneration, enabling physicians to make better clinical decisions and improve patients' quality of life. They are backed by a diverse network of experts and have a mission to be the global number one in dementia prediction technology.